Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure.

Bayes-Genis A, de Antonio M, Galán A, Sanz H, Urrutia A, Cabanes R, Cano L, González B, Díez C, Pascual T, Elosúa R, Lupón J.

Eur J Heart Fail. 2012 Jan;14(1):32-8. doi: 10.1093/eurjhf/hfr156.

2.

Combined use of the novel biomarkers high-sensitivity troponin T and ST2 for heart failure risk stratification vs conventional assessment.

Lupón J, de Antonio M, Galán A, Vila J, Zamora E, Urrutia A, Bayes-Genis A.

Mayo Clin Proc. 2013 Mar;88(3):234-43. doi: 10.1016/j.mayocp.2012.09.016. Epub 2013 Feb 4. Erratum in: Mayo Clin Proc. 2013 May;88(5):532.

PMID:
23384388
3.

Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3.

Bayes-Genis A, de Antonio M, Vila J, Peñafiel J, Galán A, Barallat J, Zamora E, Urrutia A, Lupón J.

J Am Coll Cardiol. 2014 Jan 21;63(2):158-66. doi: 10.1016/j.jacc.2013.07.087. Epub 2013 Sep 24.

4.

Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure.

de Antonio M, Lupon J, Galan A, Vila J, Urrutia A, Bayes-Genis A.

Am Heart J. 2012 May;163(5):821-8. doi: 10.1016/j.ahj.2012.03.004.

PMID:
22607860
5.

Impact of diabetes on the predictive value of heart failure biomarkers.

Alonso N, Lupón J, Barallat J, de Antonio M, Domingo M, Zamora E, Moliner P, Galán A, Santesmases J, Pastor C, Mauricio D, Bayes-Genis A.

Cardiovasc Diabetol. 2016 Nov 3;15(1):151.

6.

Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure.

Ahmad T, Fiuzat M, Neely B, Neely ML, Pencina MJ, Kraus WE, Zannad F, Whellan DJ, Donahue MP, Piña IL, Adams KF, Kitzman DW, O'Connor CM, Felker GM.

JACC Heart Fail. 2014 Jun;2(3):260-8. doi: 10.1016/j.jchf.2013.12.004.

7.

High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure.

Ky B, French B, McCloskey K, Rame JE, McIntosh E, Shahi P, Dries DL, Tang WH, Wu AH, Fang JC, Boxer R, Sweitzer NK, Levy WC, Goldberg LR, Jessup M, Cappola TP.

Circ Heart Fail. 2011 Mar;4(2):180-7. doi: 10.1161/CIRCHEARTFAILURE.110.958223. Epub 2010 Dec 22.

8.

Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure.

Rehman SU, Mueller T, Januzzi JL Jr.

J Am Coll Cardiol. 2008 Oct 28;52(18):1458-65. doi: 10.1016/j.jacc.2008.07.042.

9.

ST2 pathogenetic profile in ambulatory heart failure patients.

Bayes-Genis A, Januzzi JL, Gaggin HK, de Antonio M, Motiwala SR, Zamora E, Galán A, Domingo M, Urrutia A, Lupón J.

J Card Fail. 2015 Apr;21(4):355-61. doi: 10.1016/j.cardfail.2014.10.014. Epub 2014 Nov 3.

PMID:
25451702
10.

Multimarker Strategy for Heart Failure Prognostication. Value of Neurohormonal Biomarkers: Neprilysin vs NT-proBNP.

Bayes-Genis A, Barallat J, Galán A, de Antonio M, Domingo M, Zamora E, Gastelurrutia P, Vila J, Peñafiel J, Gálvez-Montón C, Lupón J.

Rev Esp Cardiol (Engl Ed). 2015 Dec;68(12):1075-84. doi: 10.1016/j.rec.2015.07.001. Epub 2015 Aug 19.

PMID:
26297179
11.

Soluble ST2 in ambulatory patients with heart failure: Association with functional capacity and long-term outcomes.

Felker GM, Fiuzat M, Thompson V, Shaw LK, Neely ML, Adams KF, Whellan DJ, Donahue MP, Ahmad T, Kitzman DW, Piña IL, Zannad F, Kraus WE, O'Connor CM.

Circ Heart Fail. 2013 Nov;6(6):1172-9. doi: 10.1161/CIRCHEARTFAILURE.113.000207. Epub 2013 Oct 8.

12.

Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure.

Pascual-Figal DA, Manzano-Fernández S, Boronat M, Casas T, Garrido IP, Bonaque JC, Pastor-Perez F, Valdés M, Januzzi JL.

Eur J Heart Fail. 2011 Jul;13(7):718-25. doi: 10.1093/eurjhf/hfr047. Epub 2011 May 6.

13.

Development of a novel heart failure risk tool: the barcelona bio-heart failure risk calculator (BCN bio-HF calculator).

Lupón J, de Antonio M, Vila J, Peñafiel J, Galán A, Zamora E, Urrutia A, Bayes-Genis A.

PLoS One. 2014 Jan 15;9(1):e85466. doi: 10.1371/journal.pone.0085466. eCollection 2014.

14.

Biomarker-assist score for reverse remodeling prediction in heart failure: The ST2-R2 score.

Lupón J, Gaggin HK, de Antonio M, Domingo M, Galán A, Zamora E, Vila J, Peñafiel J, Urrutia A, Ferrer E, Vallejo N, Januzzi JL, Bayes-Genis A.

Int J Cardiol. 2015 Apr 1;184:337-43. doi: 10.1016/j.ijcard.2015.02.019. Epub 2015 Feb 17.

PMID:
25734941
15.

Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure.

Gaggin HK, Szymonifka J, Bhardwaj A, Belcher A, De Berardinis B, Motiwala S, Wang TJ, Januzzi JL Jr.

JACC Heart Fail. 2014 Feb;2(1):65-72. doi: 10.1016/j.jchf.2013.10.005. Epub 2014 Jan 25.

PMID:
24622120
16.

Use of multiple biomarkers to improve the prediction of death from cardiovascular causes.

Zethelius B, Berglund L, Sundström J, Ingelsson E, Basu S, Larsson A, Venge P, Arnlöv J.

N Engl J Med. 2008 May 15;358(20):2107-16. doi: 10.1056/NEJMoa0707064.

17.

Clinical utility of N-terminal pro-B-type natriuretic peptide for risk stratification of patients with acute decompensated heart failure. Derivation and validation of the ADHF/NT-proBNP risk score.

Scrutinio D, Ammirati E, Guida P, Passantino A, Raimondo R, Guida V, Sarzi Braga S, Pedretti RF, Lagioia R, Frigerio M, Catanzaro R, Oliva F.

Int J Cardiol. 2013 Oct 3;168(3):2120-6. doi: 10.1016/j.ijcard.2013.01.005. Epub 2013 Feb 6.

PMID:
23395457
18.

Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart Failure.

Tang WH, Wu Y, Grodin JL, Hsu AP, Hernandez AF, Butler J, Metra M, Voors AA, Felker GM, Troughton RW, Mills RM, McMurray JJ, Armstrong PW, O'Connor CM, Starling RC.

JACC Heart Fail. 2016 Jan;4(1):68-77. doi: 10.1016/j.jchf.2015.07.015. Epub 2015 Dec 2.

PMID:
26656144
19.

The real-life value of ST2 monitoring during heart failure decompensation: impact on long-term readmission and mortality.

Llibre C, Zamora E, Caballero À, Lupón J, Ros A, Benito N, de Antonio M, Galán A, Domingo M, Bayes-Genis A.

Biomarkers. 2016;21(3):225-32. doi: 10.3109/1354750X.2015.1130747. Epub 2016 Jan 15.

PMID:
26767401
20.

ST2 may not be a useful predictor for incident cardiovascular events, heart failure and mortality.

Hughes MF, Appelbaum S, Havulinna AS, Jagodzinski A, Zeller T, Kee F, Blankenberg S, Salomaa V; FINRISK and BiomarCaRE investigators.

Heart. 2014 Nov;100(21):1715-21. doi: 10.1136/heartjnl-2014-305968. Epub 2014 Jul 30.

PMID:
25080471

Supplemental Content

Support Center